See link: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/compliance-research-and-development/good-manufacturing-practice#ema-inpage-item-10391
This measure was taken to give pharmaceutical companies more time to ensure that the quality and safety of medicines continue to be guaranteed in light of the challenges posed by the pandemic.
June 29, 2023
GMP Compliance Extended Until December 31, 2023
The European Medicines Agency (EMA) has published an update on GMP compliance in light of the COVID-19 pandemic.
This measure was taken to give pharmaceutical companies more time to ensure that the quality and safety of medicines continue to be guaranteed in light of the challenges posed by the pandemic.
Existing GMP compliance certificates are valid through December 31, 2023. This is stated in the publication dated August 11, 2022, under section 2.2 (“The validity of GMP certificates for manufacturing/importing sites of active substances and/or finished products in the EEA should be extended until the end of 2023 without the need for further action from the certificate holder.”).
The publication of these guidelines demonstrates the EMA’s commitment to addressing the challenges arising from the COVID-19 pandemic. The agency is actively working to ensure that the pharmaceutical industry continues to fulfill its responsibility to produce safe, high-quality medicines. By extending GMP compliance, companies have the opportunity to ensure that the supply of essential medicines is maintained.
Your Partner for Quality, Safety, and Compliance
The life sciences sector requires specialized knowledge and reliable support. With our comprehensive expertise, we help companies comply with laws and regulations, ensure quality, and continue to innovate with confidence.